Benzinga's Top #PreMarket Losers

shares dropped 41.05% to $6.09 in pre-market trading after the company reported top-line results from its clinical trials in organ-impaired patients.

shares fell 40.41% to $5.25 in pre-market trading after the company reported a Q3 loss of $0.15 per share on revenue of $20.80 million and issued sales forecast. Benchmark downgraded E2open from Buy to Hold and lowered price target to $6.00.

shares dropped 18.07% to $5.35 in pre-market trading after the company announced a public offering of common stock.

fell 15.12% to $37.03 in pre-market trading following updated net sales and earnings guidance for the nine weeks ended January 3, 2015.

shares declined 7.10% to $28.90 in pre-market trading after the company announced a secondary offering of 7,170,000 common units by

.